Reduction in testing and change in testing algorithm associated with decrease in number of nosocomial Clostridioides (Clostridium) difficile infections - 26/08/20
, Suzy Nichols, MD a, Michael Coogan, RN b, Jackie Opera, MT (ASCP) b, Michelle DeHart, PharmD cHighlights |
• | Current testing for Clostridioides (Clostridium) difficile infection identifies a number of false-positive test results |
• | Restrictions on testing may reduce the number of false-positive test results |
• | Substitution of cell cytoxicity assay for nucleoside amplification assay testing may also reduce the number of false-positive results |
Résumé |
Objective |
To evaluate the effects of a best practice advisory (BPA) and a change in the Clostridioides (Clostridium) difficile testing algorithm on nosocomial C. difficile infection (CDI) rates.
Methods |
This was a retrospective analysis at a tertiary care hospital of adult patients who tested positive for CDI between July 1, 2017 and September 30, 2019. In June 2018, we implemented a BPA in our electronic health record recommending against testing for CDI in patients receiving laxatives. We reviewed the number of C. difficile tests ordered before and after initiating the BPA. In December 2018, we replaced nucleic acid amplification testing (NAAT) with a cell cytotoxicity assay (CCA) for stool specimens that were enzyme immunoassay toxin negative and glutamate dehydrogenase positive.
Results |
The number of C. difficile tests ordered per month decreased 14% after implementing the BPA (P = .0001). Following this intervention, the rate of nosocomial CDI (nCDI) decreased by 16.5% (P = .33). Following substitution of CCA for NAAT for enzyme immunoassay toxin−/glutamate dehydrogenase+ specimens, there was a 50% reduction in the rate of nCDI (7.1 cases/10,000 patient days to 3.5 cases/10,000 patient days; P < .0001).
Conclusions |
Implementing a BPA to reduce inappropriate testing and changing the testing algorithm for C. difficile by substituting CCA for NAAT resulted in a lower rate of diagnosis of nCDI.
Le texte complet de cet article est disponible en PDF.Key Words : C. difficile, Nucleoside amplification assay testing, Cell cytotoxicity assay
Plan
| Abstract of data presented at IDWeek in Washington, DC in October 2019. |
|
| Conflicts of interest: PPC serves as a PI for Seres Therapeutics, Gilead, and Leonard Meron. All other authors have no conflicts of interest. |
Vol 48 - N° 9
P. 1019-1022 - septembre 2020 Retour au numéro
Article précédent
- Peripheral intravenous catheter needleless connector decontamination study—Randomized controlled trial
- Karen Slater, Marie Cooke, Fiona Fullerton, Michael Whitby, Jennine Hay, Scott Lingard, Joel Douglas, Claire M. Rickard
- Neonatal Staphylococcus aureus acquisition at a tertiary intensive care unit
- Bibi C.G.C. Slingerland, Nelianne J. Verkaik, Corné H.W. Klaassen, Willemien H.A. Zandijk, Irwin K.M. Reiss, Margreet C. Vos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?